Literature DB >> 6112770

Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity.

S Usuda, K Nishikori, O Noshiro, H Maeno.   

Abstract

A new benzamide, cis-N-(1-benzyl-2-methylpyrrolidin - 3 - yl) - 5 - chloro - 2 - methoxy - 4 - methylaminobenzamide (YM-09151-2) exhibited more potent and longer-lasting inhibitory effects on apomorphine-induced behaviours (stereotyped behaviour, emesis and hypothermia), and methamphetamine-induced stereotyped behaviour, conditioned avoidance response and open field behaviour, conditioned avoidance response and open field behaviour than either structurally similar benzamides (YM-0850 and sulpiride) or classical neuroleptics [chlorpromazine (CPZ) and haloperidol(HPD)]. Such inhibitory effects of YM-09151-2 relative to cataleptogenicity were greater than those of CPz and HPD. In contrast, sulpiride elicited few of the neuroleptic effects described above. YM-09151-2, a potent inhibitor for dopamine-sensitive adenylate cyclase (Ki: 3.0 nM) reduced, in a selective manner, the binding of [3H]dopamine to the dopamine D1 receptor (Ki:4.8 nm) associated with adenylate cyclase rather than to the dopamine D2 receptor (Ki: 0.98 microM) independent of adenylate cyclase. Sulpiride, on the contrary, inhibited only the binding to the dopamine D2 receptor, CPZ and HPD antagonized [3H]dopamine nonselectively at the two distinct dopaminergic receptors. These results suggest that YM-09151-2 is a potent and long-lasting neuroleptic with a highly selective blocking action on the dopamine D1 receptor.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6112770     DOI: 10.1007/bf00429198

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  25 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data.

Authors:  A R Cools; J M Van Rossum
Journal:  Psychopharmacologia       Date:  1976-02-02

3.  Assessment of the neuroleptic potential of some novel benzamide, butyrophenone, phenothiazine and indole derivatives.

Authors:  B Costall; W H Funderburk; C A Leonard; R J Naylor
Journal:  J Pharm Pharmacol       Date:  1978-12       Impact factor: 3.765

4.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

Review 5.  Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system.

Authors:  P F Spano; S Govoni; M Trabucchi
Journal:  Adv Biochem Psychopharmacol       Date:  1978

6.  Saturation assay for cyclic AMP using endogenous binding protein.

Authors:  B L Brown; R P Ekins; J D Albano
Journal:  Adv Cyclic Nucleotide Res       Date:  1972

7.  Antagonism of apomorphine-induced sterotypy and emesis in dogs by thioridazine, haloperidol, and pimozide.

Authors:  J Rotrosen; M B Wallach; B Angrist; S Gershon
Journal:  Psychopharmacologia       Date:  1972

8.  [The effects of sulpiride on the central nervous system].

Authors:  C Laville; J Margarit
Journal:  Pathol Biol (Paris)       Date:  1969-01

9.  Substituted benzamides as cerebral dopamine antagonists in rodents.

Authors:  P N Elliott; P Jenner; G Huizing; C D Marsden; R Miller
Journal:  Neuropharmacology       Date:  1977-05       Impact factor: 5.250

10.  A behavioural and biochemical comparison of dopamine receptor blockade produced by haloperidol with that produced by substituted benzamide drugs.

Authors:  P Jenner; A Clow; C Reavill; A Theodorou; C D Marsden
Journal:  Life Sci       Date:  1978-08-14       Impact factor: 5.037

View more
  12 in total

1.  The Behavioral and Pharmacological Actions of NMDA Receptor Antagonism are Conserved in Zebrafish Larvae.

Authors:  John Chen; Roshni Patel; Theodore C Friedman; Kevin S Jones
Journal:  Int J Comp Psychol       Date:  2010

2.  BRL 20596, a novel anilide with central dopamine antagonist activity.

Authors:  W Campbell; M S Clark; P J Mitchell; P L Needham; J M Semple
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Synergistic blockade of some dopamine-mediated behaviours by (-)-sulpiride and SCH 23390 in the rat.

Authors:  R Dall'Olio; P Roncada; A Vaccheri; O Gandolfi; N Montanaro
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse.

Authors:  S B Ross; D M Jackson; E M Wallis; S R Edwards
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

5.  Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2.

Authors:  H B Niznik; D E Grigoriadis; I Pri-Bar; O Buchman; P Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-06       Impact factor: 3.000

6.  Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats.

Authors:  J Arnt; J Hyttel
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

7.  Dopamine receptors in canine caudate nucleus.

Authors:  H Maeno
Journal:  Mol Cell Biochem       Date:  1982-03-19       Impact factor: 3.396

8.  Biochemical, behavioural, and endocrine effects of CK 204-933, a novel 8 beta-ergolene.

Authors:  R Markstein; A Enz; J M Vigouret; A Jaton; A Closse; U Briner; P Gull
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

Review 9.  Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

Authors:  Delia Bishara; David Taylor
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Synergistic effects between D-1 and D-2 dopamine antagonists on catalepsy in rats.

Authors:  F Wanibuchi; S Usuda
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.